About mePenn State Econ major~Scholar of Behavioral Finance & 30yr mkt trader~Proponent of the notion that psychology & emotion recurrently contest the efficient market hypothesis*DISCLAIMER:NEVER trade any security based on my opinions-Live Life-Smile Often
Eddie Gray (CEO) & the rest of Dynavax's "A-Team" are unequivocally committed and, IMO, well in the process of expanding/creating a diversified PL within a first class biotech franchise. I'm a firm believer that management's rigorous approach to drug development in the field of TLR biology and immune system modulation to attack the challenges of infectious and...
A familiar theme as of late. The chart is self-explanatory, depicting a violated lower trend line and corresponding support levels (S-1 - S-4). In the event the stock closes below that psychological $1.00 mark, selling will likely accelerate. For reference only. As always, these are only my opinions and not investment advice.
As noted recently, RNN needed to hold that lower, ascending trend line, but following subsequent market and sector weakness, it failed to do so (trend line has been violated). With the stock still up 289% from its 52 week low, caution is warranted, and it seems logical that further weakness is a strong possibility. How low could it go? Please see corresponding,...
Price action was encouraging at the start of the year, but following a volatile couple of months, shares of MSTX have retreated significantly from their 52 wk high. Channels with horizontal trend-lines have been pretty well defined, and the stock currently sits at another key support level. It needs to hold here, IMO, or the bleeding will likely continue. Next...
Well, that's the million dollar question. The multi-year move, unequivocally, has been one for the books, but propensity has shifted to the downside. Momentum name valuations are getting clipped, seemingly, on a daily basis, as investor de-risking broadens and continues heading into the psychological "sell in May" period. Included are several key support levels to...
In aggregate, the impressive move in biotechnology has truly been one for the books, but is it sustainable? Although the fundamentals remain intact (biotech is a growth story and, indubitably, one that's here to stay), I think it is fair to assume that we could see a pullback of at least 10% at some point in the near future. What goes up, must come down. The...
